Company intelligence / Profile preview
Alacrity Biosciences
Laguna Hills, California, United Stateslinkedin.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Alacrity Biosciences developed two main programs targeting ophthalmic diseases. ALTY‑0501, a matrix metalloproteinase inhibitor, completed a Phase 2 trial for dry eye with data presented at ARVO 2007 showing maintenance of corneal epithelial barrier integrity. ALTY‑0601, a small synthetic peptide targeting fibronectin receptors to increase aqueous outflow in glaucoma patients, showed promising pilot results but did not advance beyond early clinical development. The company is now out of business.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculesSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Alacrity Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alacrity Biosciences.